Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesTherapeutic potential for GIP receptor agonists and antagonists
Best Practice & Research Clinical Endocrinology & Metabolism, 09/21/09
Irwin N et al. – Glucose–dependent insulinotropic polypeptide (GIP or gastric inhibitory polypeptide) is a 42–amino–acid hormone, secreted from the enteroendocrine K cells, which has insulin–releasing and extrapancreatic glucoregulatory actions. Strong parallels exist with the beneficial metabolic effects of Roux–en–Y gastric bypass in obese, insulin–resistant humans that surgically ablates GIP–secreting K cells. The purpose of this article is to highlight the therapeutic potential of GIP–based therapeutics in the treatment of type 2 diabetes and obesity.
Related Articles
[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging
European Journal of Nuclear Medicine & Molecular Imaging, 10/02/09
Relevance Score: 68%
Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery
Cochrane Reviews, 10/20/09
Relevance Score: 67%
Comparison of the Anti-nociceptive and Anti-Rewarding Profiles of Novel Bifunctional Nociceptin/Orphanin FQ Receptor (NOPr)-Mu Opioid Receptor (MOPr) Ligands: Implications for Therapeutic Applications
Journal of Pharmacology and Experimental Therapeutics, 10/07/09
Relevance Score: 67%
NF546 is a non-nucleotide P2Y11 agonist and stimulates release of IL-8 from human monocyte-derived dendritic cells
Journal of Pharmacology and Experimental Therapeutics, 11/20/09
Relevance Score: 66%
Morphine/naltrexone extended-release capsules (Embeda): Combination of mu-opioid agonist and mu-opioid antagonist approved for the management of moderate-to-severe pain when continuous analgesia is needed for an extended time period
Formulary, 11/02/09
Relevance Score: 66%
Today in Obesity...keeping you current
Receive free subspecialty "5-minute updates" via email
Review of endoscopic devices for weight reduction: old and new balloons and implantable prostheses
Endoscopy, 12/07/09
Duodenal Switch Provides Superior Resolution of Metabolic Comorbidities Independent of Weight Loss in the Super-obese Compared with Gastric Bypass
Journal of Gastrointestinal Surgery, 12/07/09
New psycho-pedagogic approach to obesity treatment: A 5-year follow-up
Patient Education and Counselling, 12/07/09
Sponsor
Article Search
Sponsor